207 related articles for article (PubMed ID: 29862659)
1. ALK-rearranged lung cancer with intradural extramedullary spinal cord metastases responding to ceritinib treatment: A case report.
Xu Y; Zhong W; Chen M; Zhao J; Wang M
Thorac Cancer; 2018 Aug; 9(8):1078-1081. PubMed ID: 29862659
[TBL] [Abstract][Full Text] [Related]
2. Complete response of spinal metastases from non-small cell lung cancer with ALK inhibitors.
Pellerino A; Buffoni L; Rudà R; Soffietti R
Neurology; 2019 Jul; 93(5):217-219. PubMed ID: 31248938
[No Abstract] [Full Text] [Related]
3. Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapy.
Dudnik E; Siegal T; Zach L; Allen AM; Flex D; Yust-Katz S; Limon D; Hirsch FR; Peled N
J Clin Neurosci; 2016 Apr; 26():46-9. PubMed ID: 26677785
[TBL] [Abstract][Full Text] [Related]
4. Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.
Califano R; Greystoke A; Lal R; Thompson J; Popat S
Lung Cancer; 2017 Sep; 111():51-58. PubMed ID: 28838397
[TBL] [Abstract][Full Text] [Related]
5. Enteral Administration of TKIs: Report of a Response to Ceritinib in an ALK-positive NSCLC Patient and Literature Review.
Facchinetti F; Bordi P; Bini P; Bidin L; Camisa R; Tiseo M
Curr Drug Targets; 2018; 19(14):1649-1656. PubMed ID: 29437006
[TBL] [Abstract][Full Text] [Related]
6. Clinical Efficacy of Alectinib in Patients with
Oya Y; Yoshida T; Kuroda H; Shimizu J; Horio Y; Sakao Y; Hida T; Yatabe Y
Anticancer Res; 2017 Nov; 37(11):6477-6480. PubMed ID: 29061835
[TBL] [Abstract][Full Text] [Related]
7. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
Kim DW; Mehra R; Tan DSW; Felip E; Chow LQM; Camidge DR; Vansteenkiste J; Sharma S; De Pas T; Riely GJ; Solomon BJ; Wolf J; Thomas M; Schuler M; Liu G; Santoro A; Sutradhar S; Li S; Szczudlo T; Yovine A; Shaw AT
Lancet Oncol; 2016 Apr; 17(4):452-463. PubMed ID: 26973324
[TBL] [Abstract][Full Text] [Related]
8. [Clinical Features of Intradural Extramedullary Spinal Cord Metastases
in Primary Lung Cancer].
Xu Y; Zhong W; Zhao J; Chen M; Li L; Wang M
Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):539-44. PubMed ID: 27561805
[TBL] [Abstract][Full Text] [Related]
9. Ceritinib Treatment for Carcinomatous Meningitis with a Secondary Mutation at I1171T in Anaplastic Lymphoma Kinase.
Ashinuma H; Shingyoji M; Hasegawa Y; Yokoi S; Yoshida Y
Intern Med; 2018 Nov; 57(21):3153-3155. PubMed ID: 29877262
[TBL] [Abstract][Full Text] [Related]
10. Organizing pneumonia in ALK+ lung adenocarcinoma treated with ceritinib: A case report and literature review.
Wu Y; Chen H; Guan J; Zhang K; Wu W; Li X; Zhang J
Medicine (Baltimore); 2021 Jul; 100(26):e26449. PubMed ID: 34190169
[TBL] [Abstract][Full Text] [Related]
11. Intracranial remission with brigatinib rechallenge as fifth-line ALK inhibition therapy in a lung cancer patient.
Hochmair M; Weinlinger C; Prosch H
Anticancer Drugs; 2019 Nov; 30(10):1058-1060. PubMed ID: 31033499
[TBL] [Abstract][Full Text] [Related]
12. A Long-Term Spinal Intramedullary Response to Ceritinib in ALK Rearranged Non-Small-Cell Lung Cancer.
Biya J; Caramella C; Lindsay CR; Planchard D; Besse B
J Thorac Oncol; 2015 Jun; 10(6):e44-5. PubMed ID: 26001149
[TBL] [Abstract][Full Text] [Related]
13. Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer.
Won B; Mambetsariev I; Salgia R
BMC Cancer; 2016 Aug; 16():568. PubMed ID: 27480287
[TBL] [Abstract][Full Text] [Related]
14. Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.
Crinò L; Ahn MJ; De Marinis F; Groen HJ; Wakelee H; Hida T; Mok T; Spigel D; Felip E; Nishio M; Scagliotti G; Branle F; Emeremni C; Quadrigli M; Zhang J; Shaw AT
J Clin Oncol; 2016 Aug; 34(24):2866-73. PubMed ID: 27432917
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
Cha YJ; Kim HR; Shim HS
J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
[TBL] [Abstract][Full Text] [Related]
16. ASCEND-8 pharmacokinetic, safety, and efficacy data for ceritinib 450 mg with food in patients with anaplastic lymphoma kinase-positive non-small cell lung Cancer: A clinical perspective.
Otoukesh S; Sanchez T; Mirshahidi S; Wallace D; Mirshahidi H
Cancer Treat Res Commun; 2019; 20():100149. PubMed ID: 31075537
[TBL] [Abstract][Full Text] [Related]
17. Crizotinib primary resistance overcome by ceritinib in a patient with ALK-rearranged non-small cell lung cancer.
Facchinetti F; Caramella C; Auger N; Planchard D; Adam J; Lacroix L; Remon J; Massard C; Soria JC; Friboulet L; Besse B
Tumori; 2016 Nov; 102(Suppl. 2):. PubMed ID: 27197808
[TBL] [Abstract][Full Text] [Related]
18. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
Ou SH; Greenbowe J; Khan ZU; Azada MC; Ross JS; Stevens PJ; Ali SM; Miller VA; Gitlitz B
Lung Cancer; 2015 May; 88(2):231-4. PubMed ID: 25736571
[TBL] [Abstract][Full Text] [Related]
19. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
Croegaert K; Kolesar JM
Am J Health Syst Pharm; 2015 Sep; 72(17):1456-62. PubMed ID: 26294238
[TBL] [Abstract][Full Text] [Related]
20. ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC).
Cho BC; Kim DW; Bearz A; Laurie SA; McKeage M; Borra G; Park K; Kim SW; Ghosn M; Ardizzoni A; Maiello E; Greystoke A; Yu R; Osborne K; Gu W; Scott JW; Passos VQ; Lau YY; Wrona A
J Thorac Oncol; 2017 Sep; 12(9):1357-1367. PubMed ID: 28729021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
